Alfred Mann: Boundless Innovator
An interview with Alfred Mann, one of the device industry's most remarkable innovators, whose extraordinary technological and commercial successes extend from cardiology to cochlear implants to neurostimulation, and who is now looking to succeed where others have failed with inhaled insulin.
You may also be interested in...
A look back at the biggest devices stories of the decade, in capsule form.
Does the recent rash of follow-on public offerings mean biotech IPOs are around the corner? Recent financings provide reason to think it's possible.
The following is an excerpt from an 1interview with Mannkind founder Alfred Mann, published in the September issue of FDC-Windhover's IN VIVO. Mann explains his conviction that inhaled insulin will be a blockbuster product - despite the commercial failure of Exubera and the decision of other sponsors to drop development of other versions.